Neurocrine's NBI-1065845 Shows Promise as Adjunctive Treatment for Major Depressive Disorder
The ongoing trial of NBI-1065845 as an adjunctive treatment for Major Depressive Disorder could significantly impact Neurocrine's competitive positioning in the neurology market. Success in this trial may address unmet needs for patients not fully responding to current therapies, influencing future development strategies.
Phase III
Neurology / Major Depressive Disorder
Status
Active
Sponsor
NBI-1065845
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
The ongoing trial of NBI-1065845 as an adjunctive treatment for Major Depressive Disorder could significantly impact Neurocrine's competitive positioning in the neurology market. Success in this trial may address unmet needs for patients not fully responding to current therapies, influencing future development strategies.
Why it matters
The ongoing trial of NBI-1065845 as an adjunctive treatment for Major Depressive Disorder could significantly impact Neurocrine's competitive positioning in the neurology market. Success in this trial may address unmet needs for patients not fully responding to current therapies, influencing future development strategies.
What changed
Trial Update
Analysis
A study is underway to assess the efficacy and safety of NBI-1065845 as an adjunctive treatment for Major Depressive Disorder.
The ongoing trial of NBI-1065845 as an adjunctive treatment for Major Depressive Disorder could significantly impact Neurocrine's competitive positioning in the neurology market. Success in this trial may address unmet needs for patients not fully responding to current therapies, influencing future development strategies.
Monitor trial results and any announcements regarding efficacy and safety outcomes.
Related companies & assets
Companies
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.